Senior woman laughing

Through time


1885
 
Vaccines
Louis Pasteur treats young Joseph Meister, who had been exposed to rabies virus. This marks the first vaccination and the first vaccine against rabies.
1889
 
Diabetes
Oscar Minkowski highlighted the important role played by the pancreas in controlling blood sugar. At the same time the French physician Lanceraux established a clear distinction between the two forms of diabetes (type 1 and type 2 diabetes mellitus).
1923
 
Diabetes
First insulin (animal origin) launched by Hoechst. From 1923, date of the first insulin production, until today the lives of people with diabetes has changed radically. More than ninety years of innovation and sustained research efforts have transformed the daily lives of diabetic patients.
1936
 
Diabetes
Hoechst develops the crystallization process which allows better purification of insulin and improves its tolerance. This is the beginning of a long process of research into the treatment of the disease.
1937
 
Cardiovascular diseases
Delagrange Laboratories (acquired by Synthelabo) launches SEDO-CARENA® (aminophyllin/papaverine/phenobarbital), a cardio analgesic also known as "peace of heart." During the first half of the 20th century, Sanofi’s founding laboratories researched and made available innovative cardiovascular therapeutic solutions.
1942
 
Consumer Healthcare
Launch of Mitosyl® (dermatology) which owes its name to cell multiplication, or mitosis. The restorative cream is based on zinc oxide and fish liver.
1944
 
Vaccines
Isolation and identification of the 1st dengue serotype (in Hawaii, DEN1) and 2nd serotype (in N.Guinea, DEN2) by Sabin and Schelsinger
1948
 
Vaccines
First vaccine against influenza by Pocono Biological Laboratories at Swiftwater in Pennsylvania (USA), today Sanofi Pasteur
1949
 
Consumer Healthcare
Launch of Maalox® (Magnesium hydroxyde + Aluminium oxyde) in digestive health. Maalox® is now one of Sanofi's leading consumer healthcare brand.
1952
 
Oncology
Research in the field of antibiotics leads a team to isolate a molecule, the rufochromomycine, from streptomyces which are a strain of bacteria. This molecule, discovered by Rhône-Poulenc researchers, has interesting anticancer properties. This is the beginning of the great scientific adventure of Rhône-Poulenc in the field of oncology and at the origin of many therapeutic innovations.
1953
 
Cardiovascular Diseases
Launch of HEPT-A-MYL® (Heptaminol)
1953
 
Diabetes
Launch of the first long-acting insulin by Hoechst
1955
 
Vaccines
The first Inactivated Poliovirus Vaccine (IPV) is developed by Jonas Salk, an American biologist, at a time when the United States and Europe regularly faced devastating polio outbreaks. IPV mass production begins at Connaught Laboratories (today Sanofi Pasteur) in Toronto, Canada.
1956
 
Vaccines
Isolation and identification of the 3rd dengue serotype (DEN3) and 4th serotype (DEN4) by W. Hammon
1960
to
1970
 
Diabetes
Hoechst laboratory’s production teams integrate chromatography as a tool for purification. Trace impurities are eliminated.
1961
 
Consumer Healthcare
Doliprane® (Paracetamol) for pain and/or inflammation is launched in the form of 500 mg tablets. Beginning in the 1980s, Doliprane® is marketed in other forms (capsules, powder or suppository). Doliprane® today is one of Sanofi’s leading consumer healthcare brand.
1963
 
Consumer Healthcare
Launch of Rhinathiol® (Carbocisteine) for cough & cold.
1966
 
Cardiovascular Diseases
In the early 1960s, a new molecule, amiodarone, discovered by the French subsidiary of Laboratoire Labaz (later on acquired by Sanofi) enables the marketing of Cordarone® (amiodarone).
1968
 
Vaccines
Launch of vaccines against seasonal flu by Institut Pasteur production and Institut Mérieux, today Sanofi Pasteur
1968
 
Oncology
Cérubidine® (Daunorubicin) - obtained from a bacterial strain, it is the first anti-cancer medication marketed by Rhône-Poulenc. Since its launch in 1968, it has become the treatment of choice in the treatment of various types of leukemia.
In
the
1970s
 
Oncology
Discovered in Japan in 1966 - Bleomycin sulfate proves to be a powerful anti-cancer therapy. Developing an activity that allows it to slow the growth of cancer cells, Bellon Bleomycin® (Bléomycin sulfate) will begin in 1970 to be part of the drugs used in chemotherapy.
1972
 
Cardiovascular Diseases
 After reaching a collaboration agreement with Roussel Uclaf in 1968, Hoechst focuses its research in the cardiovascular field and launches Torental® / Trental® (pentophyxillin) in 1972 and Corvasal® (Molsidomine) in 1980.
1972
 
Consumer healthcare
Launch of Aspégic® (Acide acetylsalicylique) for pain and/or inflammation. Aspegic® becomes France’s best-selling aspirin in 1976. Originally, the aspirin active principle is extracted from the willow tree.
1973
 
Oncology
From the development of Cerubidine® (Daunorubicin) in 1968, Rhône-Poulenc researchers discover other molecules with anti-cancer properties. One of them, Rubidazone®, is awarded France’s Galien prize in 1973.
1976
 
Cardiovascular diseases
Launch of Sectral®(acébutolol)
1977
 
Vaccines
First generation vaccine against rabies cultivated from primary cells
1980
 
Cardiovascular Diseases
Synthelabo resumed studies of the mechanism of action of Diltiazem and in 1980 launched Tildiem® (Diltiazem chlorhydrate). It acquired Ela Medical, a specialist in pacemakers and defibrillators, in 1983 and launched Kerlone® (Betaxolol chlorhydrate) the same year.
1983
 
Diabetes
Hoechst launches a semi-synthetic human insulin. Hoechst is the first company to succeed with this method of production in 1976. The insulin is produced from purified pork insulin, which differs from the human protein by a single element (an amino acid). A biochemical process allows the amino acid to be replaced with one from human insulin. The efficacy and safety of insulin treatment are improved.
1984
 
Rare Diseases
1st patient with Gaucher disease treated by an enzyme replacement therapy developed by Sanofi Genzyme.
1985
 
Vaccines
Second generation vaccine against rabies cultivated from continuous cell line allowing a better industrial efficiency
1987
 
Cardiovascular Diseases
Hoechst which in the 1970s focused its research in the cardiovascular field, launches Triatec® (Ramipril) / Triace® / Delix®.
1988
 
Vaccines
World Health Organization and several partners formed the Global Polio Eradication Initiative, the largest global health program ever initiated. At that time, 350,000 people – mostly children - were paralyzed by poliovirus every year and poliomyelitis was endemic in 125 countries. Since then, Sanofi Pasteur has provided over 6 billion doses of Oral Poliovirus Vaccine (OPV) to Unicef for this program
1990
 
Oncology
Rhône-Poulenc Rorer launches Theprubicine® (Pirabucine)
1993
 
Oncology
Launched by Rhône-Poulenc Rorer, Granocyte® (lenograstim) owes its specificity to the fact that it stimulates the bone marrow of patients undergoing chemotherapy or bone marrow transplant.
1994
 
Vaccines
Collaboration between Sanofi Pasteur and the Vaccine Development Centre, University of Mahidol (Bangkok - Thailand), for the development of a dengue vaccine
1994
 
Rare Diseases
Sanofi Genzyme launches Cerezyme® (imiglucerase for injection) to treat Type 1 Gaucher disease patients.
1996
 
Oncology
Taxotere® (docetaxel) is an anti-cancer treatment from the taxoid family, an inhibitor of cancer cell division. Naturally occurring, docetaxel is obtained by means of semi-synthesis from a substance extracted from yew needles (a Yew is a specie of coniferous tree)
1996
 
Oncology
Derived from platinum, Eloxatin® (Oxaliplatin) received France’s Galien prize in 2004 for innovative therapy against cancer.
1997
 
Cardiovascular diseases
Sanofi and Bristol Myers Squibb successively co-develop and commercialize Aprovel® (Irbesartan )/ Avapro® and Plavix®(Clopidogrel)
1997
 
Consumer healthcare
Launch of Allegra® (fexofenadine) in allergies. Since January 2011, Allegra® has been available without prescription in the United States (www.chattem.com) and in Japan since November 2012.
2000
 
Diabetes
Lantus® (insulin glargine 100 units/ml), a long-acting human recombinant insulin, is launched by Sanofi
2001
 
Rare diseases
Sanofi Genzyme launches Fabrazyme® (agalsidase beta) to treat Fabry disease in Europe in 2001, and soon after in the United States and other regions.
2003
 
Rare diseases
Sanofi Genzyme and partner BioMarin launch Aldurazyme® (laronidase), a treatment for mucopolysaccharidosis (MPS) I disease.
2006
 
Vaccines
Collaboration with PDVI (Pediatric Dengue Vaccine Initiative), a consortium working to accelerate the introduction of a dengue vaccine candidate for children in endemic countries (supported by Sanofi Pasteur and the Bill and Melinda Gates Foundation).
2006
 
Rare Diseases
Sanofi Genzyme launches Myozyme® (alpha alglucosidase) for the treatment of Pompe disease.
2007
 
Diabetes
Sanofi launches Lantus® SoloSTAR®, Apidra® (insulin glulisine) SoloSTAR® and Insuman® (insulin human) SoloStar® pre-filled injection pens
2009
 
Cardiovascular Diseases
Sanofi discovers, develops and provides patients with Multaq® (Dronedarone)
2010
 
Consumer healthcare
Sanofi creates a strong Consumer Healthcare platform in the United States by the acquisition of Chattem Inc. a leading marketer and manufacturer of a broad portfolio of branded Over-The-Counter healthcare products, toiletries and dietary supplements.
2010
-
2011
 
Diabetes
An innovative partnership with AgaMatrix allows Sanofi to launch the BGStar® and iBGStar® blood glucose monitors
2010
 
Oncology
After 14 years of research and development, Jevtana® (Cabazitaxel ) is approved in the U.S. and in 2011 in Europe.
2011
 
Vaccines
Collaboration with the International Vaccine Institute to support the DVI (Dengue Vaccine Initiative), a nonprofit advocacy group focused on raising awareness of dengue fever and supporting the introduction of dengue vaccination, funded by the Bill & Melinda Gates Foundation and supported by Sanofi Pasteur.
2011
 
Consumer healthcare
Sanofi acquires BMP Sunstone and accelerates its business in China by reinforcing its Consumer Healthcare platform in the Cough & Cold and women’s health in China.
2012
 
Oncology
Sanofi and Regeneron Pharmaceuticals Inc. announce the approval of Zaltrap® (Aflibercept ) in the U.S., approved in 2013 in Europe
2012
-
2013
 
Multiple Sclerosis
Approval of Aubagio® (teriflunomide) for Multiple Sclerosis in the United-States and then in Europe.
2013
 
Vaccines
Polio cases had dropped by 99% globally, thanks to the GPEI. Only 4 countries remained endemic, including India and Nigeria. WHO recommended that all countries introduce at least one dose of IPV in their infant immunization schedule.
2013
 
Vaccines
Launch by Sanofi Pasteur of the quadrivalent influenza vaccine on the U.S. market, available in more than 20 countries in 2015.
2013
-
2014
 
Multiple Sclerosis
Approval of Lemtrada® (alemtuzumab) for Multiple Sclerosis treatment in Europe and then in the United States
2015
 
Vaccines
December 2015: Sanofi Pasteur’s dengue vaccine, Dengvaxia®, receives its first market approvals in Mexico, the Philippines, and Brazil.
2015
 
Cardiovascular diseases
Sanofi, in collaboration with Regeneron Pharmaceuticals, Inc., develops and delivers to patients Praluent® (alirocumab) for hypercholesterolemia.
2015
 
Consumer healthcare
Nasacort® AQ (Triamcinolone) against allergies is available without prescription in the United-States.
2015
 
Consumer healthcare
Sanofi initiates a transaction with Boehringer Ingelheim, which if approved, would make Sanofi the world leader in consumer healthcare.
2015
 
Diabetes
Sanofi launches Toujeo® (insulin glargine 300 units/ml), a long-acting insulin.
As
of
2015
 
Diabetes
Sanofi reinforces its commitment in diabetes by building strategic alliances and collaborations with the aim to enhance life of people living with diabetes.
As
of
2015
 
Oncology
Sanofi develops numerous alliances and collaborations in oncology to accelerate the development of innovative therapeutic solutions in the field of cancer.
2015
 
Rare Diseases
Sanofi Genzyme launches Cerdelga® (eliglustat), an oral treatment for Type 1 Gaucher disease.
2016
 
Vaccines
Sanofi Pasteur’s Dengvaxia® dengue vaccine launched in the 1st public immunization program in the Philippines; initial focus on three regions with high disease burden as part of integrated prevention efforts to help reduce significant dengue burden.
2016
 
Vaccines
In 2016, the world may experience the last case of wild polio in history. Only two countries remain endemic – Afghanistan and Pakistan. As the main provider of IPV, Sanofi Pasteur plays a key role in delivering vaccines all over the globe to secure a polio-free world. In the post-polio era, IPV will be integrated in pediatric combination vaccines for all children globally, in order to prevent any re-emergence.